L-citrulline Blood Pressure Randomized Trial: What the Evidence Says

Quick Answer

L-citrulline Blood Pressure Randomized Trial has 1 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• This hormonal shift is associated with numerous physiological changes that predispose women to a variety of health challenges, including increased cardiovascular risk, unfavorable body composition changes (such as increased fat mass and decreased lean mass), impaired metabolic function, and vascular endothelial dysfunction. [Bahari Hossein (2026); evidence level 1]
• Collectively, these changes contribute to the elevated incidence of hypertension, atherosclerosis, insulin resistance, and sarcopenia in postmenopausal women, which in turn increases their risk of major cardiovascular events, functional disability, reduced quality of life, and mortality compared to premenopausal counterparts. [Bahari Hossein (2026); evidence level 1]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For l-citrulline blood pressure randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Bahari Hossein (2026). Citrulline supplementation in postmenopausal women: a systematic review of vascular, muscular, and metabolic effects. DOI: 10.1186/s12905-026-04277-6. PMCID: PMC12918617. PMID: 41588439. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12918617/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.